Quick comparison
CagriSema (22.7% average weight loss, Phase 3) edges tirzepatide (20.9% Phase 3) in head-to-tail comparison — but tirzepatide is approved and available now. Both represent the current frontier of combination-pathway obesity pharmacotherapy.
CagriSema is the closest thing to an apples-to-apples comparison with tirzepatide among the pipeline drugs: both have Phase 3 data, both combine two hormonal pathways, and both achieve weight loss well above what semaglutide alone produces. The comparison between them reveals something interesting about how different dual-pathway approaches stack up.
The Mechanism Comparison
Tirzepatide activates GLP-1 and GIP receptors simultaneously. GIP receptor activation, in the context of GLP-1 co-activation, appears to enhance insulin secretion and may reduce some gastrointestinal side effects. The combination produced consistently better weight loss than semaglutide in trials.
CagriSema takes a different second pathway. Semaglutide handles GLP-1 receptor activation. Cagrilintide targets amylin receptors — a completely different hormonal system. Amylin is co-secreted with insulin by pancreatic beta cells. It slows gastric emptying, reduces glucagon release after meals, and produces satiety signals through mechanisms entirely distinct from GLP-1.
The implication is that both drugs achieve synergistic weight loss, but through different secondary mechanisms. This matters clinically: a patient who doesn't respond adequately to tirzepatide's GIP augmentation might respond differently to amylin augmentation, and vice versa.
REDEFINE vs SURMOUNT: Phase 3 Data
| CagriSema (REDEFINE 1) | Tirzepatide (SURMOUNT-1) | |
|---|---|---|
| Participants | 3,417 | 2,539 |
| Duration | 68 weeks | 72 weeks |
| Avg weight loss | 22.7% | 20.9% |
| ≥20% loss | ~45% | ~37% |
| ≥25% loss | ~31% | ~27% |
| Approved | No (NDA pending) | Yes (2023) |
| Available | 2026-2027 est. | Now |
Tirzepatide is the most effective approved option available today. Find providers through DawaMed.
Get My Match →Side Effect Profiles
Both drugs produce similar GLP-1-class side effects: nausea, vomiting, diarrhea, constipation — primarily during dose escalation. Tirzepatide's GIP component may reduce nausea relative to semaglutide alone. CagriSema's REDEFINE data showed a side effect profile consistent with semaglutide — no dramatically new signals attributable to cagrilintide specifically.
The Practical Question
For patients today: tirzepatide is the answer. It's available, it's approved, and it produces 20-22% average weight loss — a result that would have seemed remarkable before 2023.
For the future: CagriSema offers a mechanistically distinct second option, which matters because not all patients respond optimally to tirzepatide's GIP-based augmentation. Having a drug that achieves similar or better results through amylin augmentation expands what's available to prescribers for non-responders and partial responders.
Read the full CagriSema analysis, compare retatrutide vs tirzepatide, or see all drugs at the comparison hub.
Frequently Asked Questions
Is CagriSema more effective than Zepbound?
Phase 3 REDEFINE data showed CagriSema producing 22.7% average weight loss over 68 weeks. Tirzepatide (Zepbound) showed 20.9% average weight loss over 72 weeks. Both are clinically meaningful; CagriSema's advantage is modest.
Why does CagriSema work better than semaglutide alone?
CagriSema adds cagrilintide — a synthetic amylin analogue — to semaglutide. Amylin acts through a separate hormonal pathway (amylin receptors), slowing gastric emptying and producing satiety signals independent of GLP-1. Dual-pathway engagement appears to produce more weight loss than either alone.
When will CagriSema be approved?
Based on REDEFINE Phase 3 results and expected regulatory timelines, NDA submission could come in 2025-2026 with FDA approval possible in 2026-2027.
How does CagriSema compare to tirzepatide mechanistically?
Tirzepatide activates GLP-1 and GIP receptors. CagriSema activates GLP-1 receptors (via semaglutide) and amylin receptors (via cagrilintide). Both are dual-pathway approaches, but they target different secondary receptors.
Ready to find your match?
Answer 5 quick questions and see licensed GLP-1 programs available in your state — matched to your budget. Free. No obligation.
Get My Match — Free →